Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.
November 2019—The Centers for Medicare and Medicaid Services granted approval for a new technology add-on payment (NTAP) to T2 Biosystems’ T2Bacteria Panel, for fiscal year 2020. The T2Bacteria Panel is the first in vitro diagnostic test to receive approval for NTAP, according to the company.
November 2019—Agilent Technologies introduced its xCELLigence RTCA eSight multimode real-time cell analyzer. The research use only system provides label-free, real-time biosensor measurements and kinetic imaging of the same live cell populations independently or simultaneously.
November 2019—The FDA granted in October marketing authorization of the OraQuick Ebola Rapid Antigen Test to OraSure Technologies. The test is intended for use in patients suspected of and with signs or symptoms consistent with Ebola virus disease and when the patient meets the CDC’s Ebola virus epidemiological criteria, such as history of residence in or travel to a geographic region with active EVD transmission at the time of travel.
November 2019—MicroMedicine introduced Sorterra, an automated, microfluidics-based cell isolation and concentration system for research and development and clinical research labs. Sorterra isolates white blood cells from 3 to 75 mL of anticoagulated peripheral blood at a rate of 150 mL per hour.
November 2019—The FDA has cleared iCubate’s iC-GN Assay for the detection and identification of Gram-negative bacteria that are associated with bloodstream infection and subsequent sepsis.
November 2019—Bio SB has introduced its TintoDetector Mini Immuno staining system for immunohistochemical, immunocytochemistry, and immunofluorescence protocols in a semiautomated, open platform.
November 2019—Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBeam RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene for advanced colorectal cancer patients.
October 2019—The Project Santa Fe Foundation, which developed the concept of Clinical Lab 2.0, announced that it has filed for nonprofit 501c status and expanded its board of directors. New members of the board include health care leaders from Seattle Children’s Hospital, Intermountain Healthcare, University of Vermont, Mayo Clinic, and NorthShore University HealthSystem. “It is by design that PSFF did not trademark Clinical Lab 2.0, as we strongly believe that Clinical Lab 2.0 belongs to the health care industry, not to a single entity, and fundamentally believe that Clinical Lab 2.0 has no borders,” Khosrow Shotorbani, MBA, MT(ASCP), president and executive director of the Project Santa Fe Foundation, said in a press release. “The transition to value-based, Clinical Lab 2.0 standards will require cross-industry collaboration. We are honored to have these highly respected industry leaders join the global movement.” Project Santa Fe is a nonprofit organization founded through a collaboration of the Henry Ford Health System, Northwell Health, Geisinger Health System, and TriCore Reference Laboratories.
October 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. Pembrolizumab was approved for use in combination with platinum and fluorouracil for all patients and as a single agent for patients whose tumors express PD‑L1 (combined positive score, ≥1) as determined by an FDA‑approved test.
